Therapeutic Potential for HDAC Inhibitors in the Heart
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Reversible protein acetylation provides a central mechanism for controlling gene expression and cellular signaling events. Two pharmacological inhibitors of protein deacetylation are currently approved for the treatment of human cancer, and numerous follow-on compounds are in clinical development for oncology and non-oncology indications. The inhibitors target members of a family of enzymes known as histone deacetylases (HDACs). Surprisingly, HDAC inhibitors have also been shown to be efficacious in preclinical models of heart failure. This review highlights roles of HDACs in the heart and the therapeutic potential of HDAC inhibitors for the treatment of heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They have also been demonstrated to possess greater isoform selectivity profiles, targeting specifically only the class I subgroup of HDACs (6-10, 26, 38, 39).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [8]
Citations
Cites
1 retracted
Samant, S. A., Courson, D. S., Sundaresan, N. R., Pillai, V. B., Tan, M., Zhao, Y., Shroff, S. G., Rock, R. S., & Gupta, M. P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.163865 · Cited by 46 · cited 3×
“Improved Cardiac Contractility Work by Gupta and colleagues revealed that HDAC3 localizes to cardiac sarcomeres, implicating this deacetylase in the control of cardiac contractility (11).”
BackgroundRetractedWRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191259 · Cited by 3,908
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526 · cited 1×
“Genetic approaches for determining the roles of certain HDACs in the heart have been complicated by functional redundancy and early lethality associated with global gene deletion (100, 101).”
BackgroundEndothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222 · cited 3×
“During this process, excessive numbers of cardiac fibroblasts are produced in adult hearts in response to pressure overload (58) and myocardial infarction (59).”
BackgroundGregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456 · cited 1×
“Class I, II and IV HDACs are zinc-dependent enzymes, whereas class III HDACs, also known as sirtuins, require nicotinamide adenine dinucleotide (NAD+) for catalytic activity (13).”
BackgroundVoelkel, N. F., Quaife, R. A., Leinwand, L. A., Barst, R. J., McGoon, M. D., Meldrum, D. R., Dupuis, J., Long, C. S., Rubin, L. J., Smart, F. W., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.632208 · Cited by 1,250 · cited 2×
“Studies in genetically engineered mice and cultured cardiomyocytes have suggested a role for HDAC2 in heart failure (49, 50), although these findings remain contentious (51, 52).”
BackgroundMarks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
Borlaug, B. A., & Paulus, W. J. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq426 · Cited by 1,093 · cited 1×
“There are no FDAapproved drugs for HFpEF, and current treatments for systolic heart failure provide little benefit to patients with this condition (90, 91).”
BackgroundHaggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066 · cited 1×
“Finally, the first known HDAC6/class IIb–selective inhibitor, tubacin, was described in 2003 (39).”
BackgroundTh17 and regulatory T cells in mediating and restraining inflammation
Littman, D. R., & Rudensky, A. Y. (2010) · Cell · doi:10.1016/j.cell.2010.02.021 · Cited by 1,039 · cited 1×
“The protective effects of HDAC inhibitors in these models appear to be due to induction of regulatory T cells (Tregs), which possess potent anti-inflammatory properties (70).”
Background
Research works printed but not linked: 4
- 10.1161/hypertensionaha.110.154567 · DOI · Paper page
- 10.1111/j.1476-5381.2010.00637.x · DOI
- 10.1161/circulationaha.105.559724 · DOI · Paper page
- 10.2119/molmed.2011.00030 · DOI
Cited by
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
“Inhibitors of histone deacetylases, enzymes that regulate gene transcription, have been hypothesized to prevent cardiac fibrosis by inducing T reg cells and reducing numbers of fibrocytes 180 .”
Cardiac Energy Metabolism in Heart Failure
Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R., & Abel, E. D. (2021) · Circulation Research · doi:10.1161/circresaha.121.318241 · Cited by 1,373
Genetics and Genomics of Pulmonary Arterial Hypertension
Soubrier, F., Chung, W. K., Machado, R., Grünig, E., Aldred, M., Geraci, M., Loyd, J. E., Elliott, C. G., Trembath, R. C., Newman, J. H., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.035 · Cited by 616
“In addition it has become increasingly clear that HDAC inhibitors can be used to reduce cardiac hypertrophy and fibrosis (103).”
BackgroundLauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429
“One of the best examples is the aberrant activity of class I HDACs in t(8;21) acute myeloid leukemia, which silencesAML1 target genes involved in hematopoietic stem cell differentiation and promotion of leukemogenesis (12, 13).”
BackgroundHistone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Metadata
- Authors
- McKinsey, T. A.
- Affiliations
- University of Colorado Anschutz (US)
- Corresponding author
- McKinsey, Timothy A.
- ORCID
- McKinsey, Timothy A.
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2012-02-10
- Volume
- 52
- Issue
- 1
- Pages
- 303-319
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- OpenAlex
- W2103908660
- Semantic Scholar
- 86e56e40bfe696c7a31bd987e848c309500174da
- Cited by
- 230
- References
- 98
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 6 · 2023: 11 · 2022: 14 · 2021: 11 · 2020: 19 · 2019: 22 · 2018: 21 · 2017: 22 · 2016: 22 · 2015: 19 · 2014: 20 · 2013: 17 · 2012: 11
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Annual Review of Pharmacology and Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- histone deacetylase inhibitors, heart failure, protein acetylation, protein deacetylation, cardiac gene expression, cardiac signaling
- MeSH terms
- Acetylation, Animals, Drug Evaluation, Preclinical, Heart, Heart Failure, Histone Deacetylases, Histones, Humans, Models, Biological, Ventricular Remodeling, Models, Animal, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Potential for HDAC Inhibitors in the Heart. https://app.cochat.ai/papers/10.1146/annurev-pharmtox-010611-134712
- The paper
- McKinsey, T. A. (2012). Therapeutic Potential for HDAC Inhibitors in the Heart. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev-pharmtox-010611-134712
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.